Peer-influenced content. Sources you trust. No registration required. This is HCN.
Rare Disease Advisor
Valoctocogene roxaparvovec gene therapy demonstrates long-term efficacy in reducing bleeding episodes and factor VIII use in patients with severe hemophilia A, potentially changing the treatment landscape for this condition.
Hematology August 26th 2024
Cleveland Clinic Journal of Medicine (CCJM)
Stellate ganglion block reduces vasomotor symptom frequency by 4-90% in clinical trials, offering a potential non-hormonal option for women with severe symptoms refractory to conservative care.
Obstetrics & Gynecology August 26th 2024